cjc 1295 ipamorelin synergy gh release multiple Peptide therapy designed to help your body do what it was built to do — recover, repair, and perform. CJC-1295 and support the body's natural growth-hormone under physician supervision, helping Gift Card for Peptide Stack

Like Sermorelin, CJC-1295 stimulates GHRH receptors on pituitary somatotrophs

(Immune modulation with thymosin alpha-1 treatment.) Background mechanistic and clinical-trial sources only

Regulatory and compounding status All four compounds share a broadly similar regulatory landscape in the United States as of 2026: None are FDA-approved as finished drug products for therapeutic use All are classified as WADA S2 prohibited substances year-round All four have 503A compounding status of Under Review, meaning the FDA Pharmacy Compounding Advisory Committee (PCAC) has nominated them for evaluation but final category assignments (Category 1 permitted for compounding

Evidence based recommendations suggest selecting compounds based on specific research objectives not broad applications

Our customer care team are skincare and product experts and can guide you to the best skin of your life.